

XIAP Blocking Peptide
Catalog # PBV10072b**Specification**

XIAP Blocking Peptide - Product Information

Primary Accession	P98170
Other Accession	AAH32729
Gene ID	331
Calculated MW	56685

XIAP Blocking Peptide - Additional Information**Gene ID** 331**Application & Usage**

The peptide is used for blocking the antibody activity of XIAP. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C.

Other Names

E3 ubiquitin-protein ligase XIAP, 6.3.2.-, Baculoviral IAP repeat-containing protein 4, IAP-like protein, ILP, hILP, Inhibitor of apoptosis protein 3, IAP-3, hIAP-3, hIAP3, X-linked inhibitor of apoptosis protein, X-linked IAP, XIAP, API3, BIRC4, IAP3

Target/Specificity

XIAP

Formulation

50 µg (0.2 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 0.1% BSA and 0.02% thimerosal.

Reconstitution & Storage

-20 °C

Background Descriptions**Precautions**

XIAP Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures.

XIAP Blocking Peptide - Protein Information**Name** XIAP {ECO:0000303|PubMed:12121969, ECO:0000312|HGNC:HGNC:592}**Function**

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates

inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis (PubMed:11447297, PubMed:12121969, PubMed:9230442, PubMed:11257230, PubMed:11257231, PubMed:12620238, PubMed:17967870, PubMed:19473982, PubMed:20154138, PubMed:22103349, PubMed:17560374). Acts as a direct caspase inhibitor (PubMed:11257230, PubMed:11257231, PubMed:12620238). Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry (PubMed:11257230, PubMed:11257231, PubMed:16352606, PubMed:16916640). Inactivates CASP9 by keeping it in a monomeric, inactive state (PubMed:12620238). Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS, PTEN and BIRC5/survivin (PubMed:17967870, PubMed:19473982, PubMed:20154138, PubMed:22103349, PubMed:22607974, PubMed:30026309, PubMed:29452636, PubMed:17560374). Acts as an important regulator of innate immunity by mediating 'Lys-63'-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling (PubMed:19667203, PubMed:22607974, PubMed:30026309, PubMed:29452636). 'Lys-63'-linked polyubiquitination of RIPK2 also promotes recruitment of the LUBAC complex to RIPK2 (PubMed:22607974, PubMed:29452636). Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation (PubMed:17560374). Ubiquitination of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation (PubMed:20154138). Ubiquitination of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation (PubMed:17967870, PubMed:22103349). Plays a role in copper homeostasis by ubiquitinating COMMD1 and promoting its proteasomal degradation (PubMed:14685266). Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation (PubMed:<a

[21145488](http://www.uniprot.org/citations/21145488)). Ubiquitinates and therefore mediates the proteasomal degradation of BCL2 in response to apoptosis (PubMed:[29020630](http://www.uniprot.org/citations/29020630)). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner (PubMed:[22095281](http://www.uniprot.org/citations/22095281)). Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8 (PubMed:[22095281](http://www.uniprot.org/citations/22095281)). Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES (PubMed:[22304967](http://www.uniprot.org/citations/22304967)). Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program (PubMed:[22304967](http://www.uniprot.org/citations/22304967)).

Cellular Location

Cytoplasm. Nucleus. Note=TLE3 promotes its nuclear localization.

Tissue Location

Expressed in colonic crypts (at protein level) (PubMed:30389919). Ubiquitous, except peripheral blood leukocytes (PubMed:8654366).

XIAP Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

XIAP Blocking Peptide - Images